Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer
Endocrinology and Metabolism
;
: 388-393, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-44889
ABSTRACT
Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed. Treatment with sorafenib was begun in September 2010. After 11 months treatment of sorafenib, newly developed metastatic lesions were found in mediastinal lymph nodes, liver, and bones. Considered as treatment failure, the administration of sorafenib was discontinued. Two weeks after sorafenib treatment was stopped, the disease progressed abruptly and caused death of the patient by respiratory failure. In our patient, PTC progressed rapidly after the cessation of sorafenib treatment. Patients with several other types of cancer have also experienced such rapid disease progression, termed "flare-ups." Physicians should be aware that flare-ups may occur in advanced PTC patients following the cessation of TKI therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Insuficiencia Respiratoria
/
Tiroidectomía
/
Proteínas Tirosina Quinasas
/
Neoplasias de la Tiroides
/
Insuficiencia del Tratamiento
/
Progresión de la Enfermedad
/
Yodo
/
Hígado
/
Pulmón
Tipo de estudio:
Estudio pronóstico
Límite:
Adulto
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Endocrinology and Metabolism
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS